Gastric cancer diagnostics Market Revenue to Attain USD 2.72 Bn by 2035

Published: 23 Dec 2025

Author: Precedence Research

Share:

Gastric cancer diagnostics Market Revenue and Trends 2026 to 2035

The global gastric cancer diagnostics market revenue surpassed USD 1.32 billion in 2025 and is predicted to attain around USD 2.72 billion by 2035, growing at a CAGR of 7.51%. Several factors, including the increasing incidence of gastric cancer, a growing emphasis on personalized medicine, and rapid technological advancement in diagnostic tools, drive the market's growth.

What are the Factors That Have a Significant Contribution to the Growth of the Gastric cancer diagnostics market?

The increasing focus on early detection of gastric cancer and a surge in screening programs are the major drivers, accelerating the market's growth in the coming years.  Gastric cancer is one of the leading causes of cancer-related deaths globally, which has led to an increasing demand for advanced diagnostic tools for early and accurate diagnosis.  For instance, according to the new study published in July 2025 by scientists at the International Agency for Research on Cancer (IARC), which projects the future burden of gastric cancer, including that attributable to Helicobacter pylori infection, the primary cause of gastric cancer among a cohort of individuals born in 2008-2017.

The expected and preventable gastric cancers across 185 countries were estimated by combining national age-specific incidence rates from GLOBOCAN 2022 and cohort-specific mortality rates from United Nations demographic projections.  Worldwide, 15.6 million gastric cancer cases are expected to occur within these birth cohorts, of which 76% are attributable to H. pylori infection and are therefore potentially preventable. Asia accounted for two-thirds of the expected cases, followed by the Americas and Africa. Additionally, technological innovations, such as liquid biopsy, next generation sequencing (NGS), and AI-powered diagnostic tools, enable more accurate and earlier detection of gastric cancer, driving growth in the gastric cancer diagnostics market during the forecast period.

Segment Insights

• By diagnostic method, the endoscopy segment led the market in 2025, holding the largest share, owing to the increasing demand for early detection to improve patient treatment outcomes and survival rates. Endoscopy is widely used for detecting stomach cancer, as it allows direct visualization of the gastric lining and collection of tissue samples (for definitive diagnosis). Endoscopy, combined with advanced techniques such as high-definition (HD) cameras and AI-assisted diagnostics, enables the detection of early-stage lesions that might otherwise be missed.
• By technology, the next-generation sequencing segment held the largest market share in 2025. Next-generation sequencing (NGS) enables earlier and more accurate detection and monitoring of the disease, thereby improving patient outcomes. NGS analysis of gastric cancer accurately identifies the leukemia inhibitory factor receptor (LIFR) as a potential driving factor in gastric cancer progression.
• By end-user, the hospitals segment accounted for the largest share in 2025. Hospitals are a major end user in the gastric cancer diagnostics market, owing to their advanced diagnostic services and ongoing technological advancements in molecular diagnostics, immunoassays, and next-generation sequencing to manage large patient volumes. Hospitals are performing complex procedures such as endoscopy, biopsy, and advanced imaging.

Regional Insights

North America holds the dominant share in the global gastric cancer diagnostics market. The presence of sophisticated healthcare infrastructure drives the region’s leadership, the increasing emphasis on personalized medicine, the rising burden of gastric cancer, and a surge in government-funded screening programs. For instance, in April, 2025,  The National Institutes of Health (NIH) has granted Cleveland Clinic’s Michelle Kang Kim, MD, PhD, a 5-year, USD 2.6 million award to lead a nationwide team of researchers, clinicians and computer scientists in assessing the feasibility of gastric cancer screening in the U.S. She and her team to use federated learning techniques to test a predictive model for gastric cancer screening on a national scale. Moreover, ongoing technological improvements in NGS technologies enhance efficiency, accuracy, and the ability to analyze large volumes of genomic data rapidly, propelling growth in the gastric cancer diagnostics market. Such a combination of factors is likely to fuel the region's expansion in the coming years.

On the other hand, the Asia Pacific region is anticipated to grow at the fastest rate in the market during the forecast period. The region's fastest growth is attributed to rising investments in diagnostic infrastructure, rapid technological progress in gastric cancer diagnostic tools, an increasing emphasis on screening programs and early detection, and a supportive government framework. In addition, the increasing patient population with gastric cancer, along with the rising number of clinics, hospitals, and diagnostic laboratories, is expected to drive growth in the Asia Pacific region.

Gastric cancer diagnostics Market Coverage

Recent Developments

• In November 2025, Roche Diagnostics announced the launch of its locally made Elecsys PGI and Elecsys PGII tests in China. These tests offer a highly accurate and non-invasive method for early screening and risk assessment of gastric cancer and atrophic gastritis.(Source: https://www.citynewsservice.cn)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7230

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344